Sclerosis
Welcome,         Profile    Billing    Logout  
 125 Companies   183 Products   183 Products   133 Mechanisms of Action   1 Trial   2306 News 


«12...1112131415161718192021...4041»
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date:  Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns (clinicaltrials.gov) -  Feb 19, 2015   
    P4,  N=120, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2014 --> Jul 2015 Recruiting --> Active, not recruiting | N=240 --> 120 | Trial primary completion date: Jun 2015 --> Mar 2015
  • ||||||||||  dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
    Enrollment closed:  Clinical Trial Nuedexta in Subjects With ALS (clinicaltrials.gov) -  Feb 19, 2015   
    P2,  N=60, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=240 --> 120 | Trial primary completion date: Jun 2015 --> Mar 2015 Recruiting --> Active, not recruiting
  • ||||||||||  amphetamine/dextroamphetamine ER / Generic mfg.
    Trial completion, Trial primary completion date:  Adderall XR and Processing Speed in Multiple Sclerosis (MS) (clinicaltrials.gov) -  Feb 19, 2015   
    P2/3,  N=70, Completed, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Completed | Trial primary completion date: Sep 2013 --> Feb 2013
  • ||||||||||  Trial primary completion date:  Acupuncture or MBSR for Patients With Fatigue and MS (clinicaltrials.gov) -  Feb 9, 2015   
    P=N/A,  N=141, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jul 2015
  • ||||||||||  pepinemab (VX15) / Vaccinex
    Trial completion, Trial primary completion date:  Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS (clinicaltrials.gov) -  Feb 6, 2015   
    P1,  N=50, Completed, 
    Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014
  • ||||||||||  amiloride hydrochloride / Generic mfg.
    Enrollment closed, Trial primary completion date:  ACTION: Amiloride Clinical Trial In Optic Neuritis (clinicaltrials.gov) -  Feb 5, 2015   
    P2,  N=46, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Nov 2015
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  MS-NANOSE: Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples (clinicaltrials.gov) -  Feb 5, 2015   
    P1,  N=71, Completed, 
    Recruiting --> Completed | N=400 --> 314 | Trial primary completion date: Dec 2014 --> Feb 2014 Active, not recruiting --> Completed | N=100 --> 71 | Trial primary completion date: Aug 2015 --> Nov 2011
  • ||||||||||  Trial primary completion date:  Lipoic Acid as a Treatment for Acute Optic Neuritis (clinicaltrials.gov) -  Feb 5, 2015   
    P1,  N=54, Recruiting, 
    Active, not recruiting --> Completed | N=100 --> 71 | Trial primary completion date: Aug 2015 --> Nov 2011 Trial primary completion date: Oct 2013 --> Oct 2015
  • ||||||||||  Trial completion, Trial primary completion date:  Low Fat Diet and Multiple Sclerosis (clinicaltrials.gov) -  Feb 5, 2015   
    P1,  N=61, Completed, 
    Trial primary completion date: Oct 2013 --> Oct 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jul 2014
  • ||||||||||  Rebif (human IFN-?-1a) / EMD Serono
    Trial termination, Trial primary completion date, Adherence:  EMR 200136-567: Adherence Trial With MS LifeLines  (clinicaltrials.gov) -  Feb 2, 2015   
    P=N/A,  N=306, Terminated, 
    Trial primary completion date: Aug 2014 --> Jun 2015 Active, not recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Jan 2015; The study was terminated as per the Sponsor's decision.
  • ||||||||||  Enrollment closed, Trial primary completion date:  Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Jan 22, 2015   
    P=N/A,  N=80, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2012 --> Jun 2014
  • ||||||||||  Betaseron (IFN-?-1b) / Bayer
    Enrollment change, Immunomodulating:  Depression and Fatigue in MS Patients Treated With Betaferon. (clinicaltrials.gov) -  Jan 22, 2015   
    P=N/A,  N=567, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2012 --> Jun 2014 N=252 --> 567
  • ||||||||||  Enrollment open, Trial primary completion date:  A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Jan 22, 2015   
    P1,  N=25, Recruiting, 
    N=252 --> 567 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Jan 2016
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Trial completion, Trial primary completion date:  PK and PD Study of Natalizumab in Pediatric Subjects With RRMS (clinicaltrials.gov) -  Jan 20, 2015   
    P1,  N=13, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014
  • ||||||||||  Extavia (IFN-β-1b) / Novartis
    Trial completion, Enrollment change, Trial primary completion date:  EPOC: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (clinicaltrials.gov) -  Jan 8, 2015   
    P4,  N=62, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Completed | N=200 --> 62 | Trial primary completion date: Sep 2014 --> Jun 2014
  • ||||||||||  Trial completion, Phase classification, Trial primary completion date:  A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients (clinicaltrials.gov) -  Jan 8, 2015   
    P=N/A,  N=27, Completed, 
    Recruiting --> Completed | N=200 --> 62 | Trial primary completion date: Sep 2014 --> Jun 2014 Active, not recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Feb 2013 --> Jun 2013
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Trial completion:  A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif (clinicaltrials.gov) -  Jan 8, 2015   
    P2,  N=334, Completed, 
    Active, not recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Feb 2013 --> Jun 2013 Active, not recruiting --> Completed